Korioretinitis Toksoplasmosis pada Penderita Imunokompeten
DOI:
https://doi.org/10.29303/jku.v5i4.7Abstract
Toksoplasmosis merupakan penyakit sistemik yang disebabkan parasit protozoa koksidia Toxoplasma gondii, infeksi biasanya tanpa gejala atau muncul dalam bentuk akut dengan gejala limfadenopati atau dengan gejala menyerupai flu (flu-like symptoms). Pada infeksi primer, penderita biasanya asimtomatik dan kadang hanya bergejala seperti demam, limfadenopati dan limfositosis yang berlangsung sampai berhari-hari atau beberapa minggu. Kami akan membahas lebih dalam sebuah kasus chorioretinitis toksoplasmosis pada penderita imunokompeten baik dari gejala klinis dan terapinyaReferences
1. Weiss LM, & Dubey JP. Toxoplasmosis: A history of clinical observation. Int J Parasit. 2009;(39):895–901.
2. Singh D, Sinert R. Toxoplasmosis. eMedicine Emergency Medicine. 2015;Available from: www.emedicine.medscape.com.
3. Wu L, Evans T, Garcia RA. Toxoplasmosis: Overview. eMedicine Ophtalmology. 2007;Available from: www.emedicine.medscape.com.
4. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. American journal of epidemiology. 2001;154(4):357–365.
5. Holland GN. Ocular toxoplasmosis: a global reassessment:. Part I: epidemiology and course of disease. American journal of ophthalmology. 2003;136(6):973–988.
6. Kravetz JD, Federman DG. Cat-associated zoonoses. Archives of Internal Medicine. 2002;162(17):1945–1952.
7. Villarreal MR. File:Toxoplasmosis life cycleen.svg; 2010. Available from: https://commons.wikimedia.org wiki/File:Toxoplasmosis_life_cycle_en.svg#file.
8. Holland GN, Lewis KG, O’Connor GR. Ocular toxoplasmosis: a 50th anniversary tribute to the contributions of Helenor Campbell Wilder Foerster. Archives of Ophthalmology. 2002;120(8):1081–1084.
9. Suhardjo, Utomo PT, Agni AN. Clinical Manifestations Of Ocular Toxoplasmosis In Yogyakarta, Indonesia: A Clinical Review Of 173 Cases. Southeast Asian J Trop Med Public Health. 2003;2(34):291–7.
10. Holland GN. Ocular toxoplasmosis: a global reassessment: part II: disease manifestations and management. American journal of ophthalmology. 2004;137(1):1–17.
11. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clinical microbiology reviews. 2000;13(4):662–685.
12. Holland GN, Crespi CM, ten Dam-van Loon N, Charonis AC, Yu F, Bosch-Driessen LH, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. American journal of ophthalmology. 2008;145(6):1007–1013.
13. Eckert G, Melamed J, Menegaz B. Optic nerve changes in ocular toxoplasmosis. Eye. 2007;21(6):746–751.
14. Dodds EM, Holland GN, Stanford MR, Yu F, Siu WO, Shah KH, et al. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. American journal of ophthalmology. 2008;146(6):856–865.
15. Gray H. Anatomy of the Human Body; 2000. Available from: http://www.bartleby.com/107/.
16. Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. Journal of clinical microbiology. 2004;42(3):941–945.
17. Paul M. Immunoglobulin G avidity in diagnosis of toxoplasmic lymphadenopathy and ocular toxoplasmosis. Clinical and diagnostic laboratory immunology. 1999;6(4):514–518.
18. Tayuksel M, Guney C, Araz E, Saracli MA, Doganci L. Performance of the Immunoglobulin G Avidity and Enzyme Immunoassay IgG/IgM Screening Tests for Differentiation of the Clinical Spectrum of toxoplasmosis. Journal of Microbiology. 2004;3(43):211–5.
19. Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann Ist Super Sanita. 2004;40(1):81–8.
20. Torre A, Gonzalez G, D ´ ´ ıaz-Ramirez J, Gomez- ´ Mar´ ın JE. Screening by Ophthalmoscopy for Toxoplasma Retinochoroiditis in Colombia. Am J Ophthalmol. 2007;(143):354 –6.
21. Villard O, Filisetti D, Roch-Deries F, Garweg J, Flament J, Candolfi E. Enzyme-Linked Immunosorbent Assay, Immunoblotting, and PCR for Diagnosis of Toxoplasmic Chorioretinitis. J Clin Microbiol. 2003;8(41):3537–41.
22. Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist’s office: are a patient’s eye symptoms serious. Cleve Clin J Med. 2005;72(4):329–39.
23. Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: An evidence-based systematic review. Ophthalmology.
2003;(110):926–32.
24. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis 1, 2. Elsevier; 2002.
25. Bovey EH. Usefulness of vitrectomy in the treatment of ocular toxoplasmosis. International journal of medical sciences. 2009;6(3):139.
26. Guex-Crosier Y. Update on the treatment of ocular toxoplasmosis. Int J Med Sci. 2009;6(3):140–2.
27. Soheilian M, Sadoughi MM, Dehghan MH, Behboudi H, Anisian A, Yazdani S. Prospective Randomized Trial of Trimethoprim/Sulfamethoxazole
versus Pyrimethamine and Sulfadiazine in the Treatment of Ocular Toxoplasmosis. Am Ac Ophtalmol.2005;(112):1876–82.
28. Rothova A, Bosch-Driessen LE, Van Loon NH, Treffers WF. Azithromycin for ocular toxoplasmosis. British journal of ophthalmology. 1998;82(11):1306–1308.
29. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. American journal of ophthalmology. 2002;134(1):34–40.
30. Ng P, McCluskey P. Treatment of ocular toxoplasmosis. Australian Prescriber. 2002;25(4):88–89.
2. Singh D, Sinert R. Toxoplasmosis. eMedicine Emergency Medicine. 2015;Available from: www.emedicine.medscape.com.
3. Wu L, Evans T, Garcia RA. Toxoplasmosis: Overview. eMedicine Ophtalmology. 2007;Available from: www.emedicine.medscape.com.
4. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. American journal of epidemiology. 2001;154(4):357–365.
5. Holland GN. Ocular toxoplasmosis: a global reassessment:. Part I: epidemiology and course of disease. American journal of ophthalmology. 2003;136(6):973–988.
6. Kravetz JD, Federman DG. Cat-associated zoonoses. Archives of Internal Medicine. 2002;162(17):1945–1952.
7. Villarreal MR. File:Toxoplasmosis life cycleen.svg; 2010. Available from: https://commons.wikimedia.org wiki/File:Toxoplasmosis_life_cycle_en.svg#file.
8. Holland GN, Lewis KG, O’Connor GR. Ocular toxoplasmosis: a 50th anniversary tribute to the contributions of Helenor Campbell Wilder Foerster. Archives of Ophthalmology. 2002;120(8):1081–1084.
9. Suhardjo, Utomo PT, Agni AN. Clinical Manifestations Of Ocular Toxoplasmosis In Yogyakarta, Indonesia: A Clinical Review Of 173 Cases. Southeast Asian J Trop Med Public Health. 2003;2(34):291–7.
10. Holland GN. Ocular toxoplasmosis: a global reassessment: part II: disease manifestations and management. American journal of ophthalmology. 2004;137(1):1–17.
11. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clinical microbiology reviews. 2000;13(4):662–685.
12. Holland GN, Crespi CM, ten Dam-van Loon N, Charonis AC, Yu F, Bosch-Driessen LH, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. American journal of ophthalmology. 2008;145(6):1007–1013.
13. Eckert G, Melamed J, Menegaz B. Optic nerve changes in ocular toxoplasmosis. Eye. 2007;21(6):746–751.
14. Dodds EM, Holland GN, Stanford MR, Yu F, Siu WO, Shah KH, et al. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. American journal of ophthalmology. 2008;146(6):856–865.
15. Gray H. Anatomy of the Human Body; 2000. Available from: http://www.bartleby.com/107/.
16. Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. Journal of clinical microbiology. 2004;42(3):941–945.
17. Paul M. Immunoglobulin G avidity in diagnosis of toxoplasmic lymphadenopathy and ocular toxoplasmosis. Clinical and diagnostic laboratory immunology. 1999;6(4):514–518.
18. Tayuksel M, Guney C, Araz E, Saracli MA, Doganci L. Performance of the Immunoglobulin G Avidity and Enzyme Immunoassay IgG/IgM Screening Tests for Differentiation of the Clinical Spectrum of toxoplasmosis. Journal of Microbiology. 2004;3(43):211–5.
19. Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann Ist Super Sanita. 2004;40(1):81–8.
20. Torre A, Gonzalez G, D ´ ´ ıaz-Ramirez J, Gomez- ´ Mar´ ın JE. Screening by Ophthalmoscopy for Toxoplasma Retinochoroiditis in Colombia. Am J Ophthalmol. 2007;(143):354 –6.
21. Villard O, Filisetti D, Roch-Deries F, Garweg J, Flament J, Candolfi E. Enzyme-Linked Immunosorbent Assay, Immunoblotting, and PCR for Diagnosis of Toxoplasmic Chorioretinitis. J Clin Microbiol. 2003;8(41):3537–41.
22. Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist’s office: are a patient’s eye symptoms serious. Cleve Clin J Med. 2005;72(4):329–39.
23. Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: An evidence-based systematic review. Ophthalmology.
2003;(110):926–32.
24. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis 1, 2. Elsevier; 2002.
25. Bovey EH. Usefulness of vitrectomy in the treatment of ocular toxoplasmosis. International journal of medical sciences. 2009;6(3):139.
26. Guex-Crosier Y. Update on the treatment of ocular toxoplasmosis. Int J Med Sci. 2009;6(3):140–2.
27. Soheilian M, Sadoughi MM, Dehghan MH, Behboudi H, Anisian A, Yazdani S. Prospective Randomized Trial of Trimethoprim/Sulfamethoxazole
versus Pyrimethamine and Sulfadiazine in the Treatment of Ocular Toxoplasmosis. Am Ac Ophtalmol.2005;(112):1876–82.
28. Rothova A, Bosch-Driessen LE, Van Loon NH, Treffers WF. Azithromycin for ocular toxoplasmosis. British journal of ophthalmology. 1998;82(11):1306–1308.
29. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. American journal of ophthalmology. 2002;134(1):34–40.
30. Ng P, McCluskey P. Treatment of ocular toxoplasmosis. Australian Prescriber. 2002;25(4):88–89.
Published
2017-03-23
How to Cite
Anggoro, J. (2017). Korioretinitis Toksoplasmosis pada Penderita Imunokompeten. Jurnal Kedokteran, 5(4). https://doi.org/10.29303/jku.v5i4.7
Issue
Section
Case Report
